How FDA clears surgical robots: 510(k), De Novo and PMA explained with Hugo, Ottava and da Vinci examples, review clocks, user fees and what to watch.
Last updated: November 21, 2026
Most surgical robots reach the US market through a 510(k), showing they are substantially equivalent to a cleared system such as da Vinci. A truly new design with no predicate goes through De Novo, as J&J’s Ottava did in July 2026. New procedures usually mean a new 510(k).
Scope: the FDA premarket pathways for robotically assisted surgical devices, how recent systems used them, and what the FDA’s 2026 draft guidance and autonomy discussion paper add.
What FDA pathway do surgical robots use?
The default is the 510(k) premarket notification. The FDA classifies the core soft tissue robot as product code NAY, “System, Surgical, Computer Controlled Instrument,” a Class II device under 21 CFR 876.1500 with 510(k) as the submission type, per the FDA classification database.
The first da Vinci system, then called the “Intuitive Surgical Endoscopic Instrument Control System,” was cleared under K990144 on July 11, 2000, under that same NAY code. Every later system that can point to it, or to a descendant, as a predicate can use the 510(k) route. Intuitive’s da Vinci 5 was cleared through a 510(k) in March 2024, per the company.
A system that is different enough that no predicate fits goes through De Novo classification. Truly high risk devices that cannot be put in Class II with special controls need premarket approval (PMA), but we found no current soft tissue surgical robot on that path.
How is a 510(k) different from De Novo and PMA?
A 510(k) argues sameness. A De Novo argues that a new device type is safe and effective enough for Class II with special controls. A PMA has to prove safety and effectiveness on its own evidence.
| Pathway | What you show | MDUFA V review goal | FY2027 standard fee (small business) |
|---|---|---|---|
| 510(k) | Substantial equivalence to a legally marketed predicate | Decision within 90 FDA days for 95% of submissions | $28,653 ($7,163) |
| De Novo | No predicate exists; general and special controls give reasonable assurance of safety and effectiveness | Decision within 150 FDA days for 70% of requests | $191,020 ($47,755) |
| PMA | Independent valid scientific evidence of safety and effectiveness | 180 FDA days without an advisory panel, 320 with one, for 90% | $636,732 ($159,183) |
“FDA days” exclude time the clock is stopped waiting on the sponsor, so calendar time runs longer. The MDUFA V commitment letter sets an average total time to decision goal of 112 calendar days for 510(k)s in FY2025 through FY2027. The FDA’s 510(k) page notes that substantial equivalence “does not mean the new and predicate devices need to be identical.”
Why did J&J’s Ottava use De Novo instead of a 510(k)?
Ottava’s arms are built into the operating table, and the FDA treated that as a new device type. The agency granted De Novo DEN250068 to Auris Health, part of J&J MedTech, on July 21, 2026, and J&J announced it the next day.
The order created a new regulation, 21 CFR 878.4966, “Integrated operating table electromechanical surgical system,” product code SIR, Class II with 16 special controls. Those controls include clinical performance testing, human factors testing, a device specific training program with distribution limited to facilities that implement it, and annual reporting. The FDA determined postmarket surveillance was not required.
J&J said the authorization covers 10 upper abdominal general surgery procedures, including gastric bypass, cholecystectomy, gastrectomy and hiatal hernia repair, with an inguinal hernia trial still running. MedTech Dive reported on November 20 that Memorial Hermann Texas Medical Center in Houston will be the first US hospital to use Ottava in J&J’s early access commercial program.
The strategic payoff of De Novo: Ottava is now a predicate. The FDA’s De Novo page says a granted device “may now serve as a predicate device for 510(k) submissions.” The next table mounted robot, from J&J or a rival, can likely take the cheaper, faster 510(k) route against it.
How does a robot add new procedures after clearance?
Usually through another 510(k) that expands the indications. Medtronic’s Hugo is the clearest live example.
Hugo was first cleared in the US on December 3, 2025 for urologic procedures including prostatectomy, nephrectomy and cystectomy. On November 17, 2026 Medtronic announced “an expanded U.S. 510(k)” that “covers all upper abdominal general surgical procedures, including but not limited to cholecystectomy,” gastric bypass, ventral hernia and small bowel resection, plus inguinal hernia and appendectomy. Medtronic says those procedures add up to about 3.5 million US surgeries a year, more than half of all US soft tissue procedures, and that Hugo is on track to pass 50,000 procedures globally by the end of its fiscal year.
| System | Company | Pathway | Date | Scope |
|---|---|---|---|---|
| da Vinci (original) | Intuitive | 510(k) K990144 | July 11, 2000 | Endoscopic instrument control |
| da Vinci 5 | Intuitive | 510(k) | March 2024 | Fifth generation multiport system |
| Versius | CMR Surgical | De Novo | October 2024 | Cholecystectomy in adults 22 and older |
| Dexter L6 | Distalmotion | 510(k) K260653 | June 11, 2026 | Inguinal hernia, cholecystectomy, benign hysterectomy, sacrocolpopexy |
| Ottava | J&J MedTech | De Novo DEN250068 | July 21, 2026 | 10 upper abdominal procedures |
| Hugo | Medtronic | 510(k), expanded | Nov 17, 2026 | Upper abdominal general surgery plus inguinal hernia and appendectomy |
Each new instrument is also a clearance question. Medtronic separately announced FDA clearance of its LigaSure RAS Maryland instrument for Hugo in September 2026.
Does clearance mean a robot is proven better than standard surgery?
No. Clearance is about safety and effectiveness for the cleared uses, often judged against a predicate, not about outcomes versus open or laparoscopic surgery.
The FDA’s computer assisted surgical systems page says the agency has not granted marketing authorization to any robotically assisted surgical system for the prevention or treatment of cancer specifically, and that there is “little evidence” for use in mastectomy. A 2019 FDA brief warned that “the survival benefits to patients when compared to traditional surgery have not been established” for cancer procedures. The same page notes these systems are “not actually a robot because it cannot perform surgery without direct human control.”
What about autonomous and remote surgical robots?
This is where the pathway question is open. In November 2026 the FDA published a discussion paper, “Evaluating Benefit-Risk in Robotic Medical Devices with Autonomous or Remote Teleoperation Capabilities,” which it says “does not represent draft or final guidance.” It treats autonomy as a spectrum, defines remote teleoperation as control without the user in the room, and asks 15 questions on terminology, automation bias, distance risk, emergency conversion, cybersecurity and postmarket oversight. It does not say which premarket pathway applies.
A public workshop runs December 2 and 3, 2026, and comments are due January 5, 2027 under docket FDA-2026-N-13135, according to the American Hospital Association.
Industry is not waiting. MedTech Dive reported on November 20 that Zimmer Biomet has filed a 510(k) for an autonomous version of its Monogram knee robot and hopes for clearance and a launch in 2027, ahead of its original 2028 plan. Whether the FDA accepts a 510(k) for autonomous cutting, or pushes it toward De Novo, will be the first real answer to the questions in the discussion paper.
What does the 2026 draft guidance on robotic surgery cover?
In September 2026 the FDA issued draft guidance, “Robotically-Assisted Surgical Devices: Premarket Submissions,” covering non clinical testing, clinical data and labeling for teleoperated, software controlled systems. Comments are due November 24, 2026 under docket FDA-2026-N-9505. We have not reviewed the full draft text, so we do not characterize its specific testing recommendations here.
Checklist: choosing a pathway for a surgical robot (our framework)
- Map your architecture to existing product codes first: NAY for computer controlled instrument systems, SIR for table integrated arms, and the regulation behind each.
- Pick a predicate whose intended use and technology match yours closely; a mismatch on either is the most common reason a 510(k) turns into a De Novo conversation.
- If nothing fits, budget for De Novo: a fee above $190,000 for FY2027, a 150 FDA day goal, and special controls you will help write and then live with.
- Use a Q-Submission early to test your pathway and clinical data plan with the FDA before you build the file.
- Plan indication expansion as a series of 510(k)s, each backed by procedure specific data, rather than one broad first claim.
- Treat training, human factors and cybersecurity as core evidence, not appendices; the Ottava special controls show where the FDA looks.
- Avoid cancer outcome claims unless you have data specific to that use.
- For any autonomous function, file comments on the discussion paper and plan for questions on emergency conversion and automation bias.
What to watch next
- November 24, 2026: comment deadline on the robotically assisted surgical devices draft guidance.
- December 2 and 3, 2026: FDA workshop on autonomous and remote teleoperation robots.
- January 5, 2027: discussion paper comments due.
- The FDA’s response to Zimmer’s autonomous Monogram 510(k).
- Ottava’s first US installs and whether a rival files a 510(k) citing it as predicate.
- Hugo’s general surgery ramp against da Vinci in hospitals that already own Intuitive systems.
Frequently asked questions
Are surgical robots FDA approved or FDA cleared?
Most are cleared through a 510(k) or granted through De Novo. “Approved” technically refers to the PMA pathway, which current soft tissue surgical robots generally do not use.
What product code covers surgical robots?
The classic console based system falls under NAY, “System, Surgical, Computer Controlled Instrument,” Class II under 21 CFR 876.1500. Newer designs have their own codes, such as SIR for table integrated systems.
When was the first da Vinci cleared?
The FDA database lists K990144, the Intuitive Surgical Endoscopic Instrument Control System, as cleared on July 11, 2000.
How long does a 510(k) for a surgical robot take?
The MDUFA V goal is a decision within 90 FDA days for 95% of 510(k)s, with an average total time goal of 112 calendar days. Complex robot files often take longer because the clock stops while the sponsor answers questions.
How long does a De Novo take?
The MDUFA V goal is a decision within 150 FDA days for 70% of De Novo requests.
How much does a De Novo cost in user fees?
For FY2027 the standard De Novo fee is $191,020, or $47,755 for qualifying small businesses, versus $28,653 for a standard 510(k).
Why is Medtronic’s Hugo a 510(k) and Ottava a De Novo?
Hugo could rely on existing predicates, and its general surgery expansion was filed as an expanded 510(k). Ottava’s table integrated arms had no predicate, so the FDA created a new device type for it.
Can a De Novo device become a predicate?
Yes. Once a De Novo is granted, the FDA says the device may serve as a predicate for future 510(k) submissions.
Does FDA clearance mean robotic surgery is better for cancer?
No. The FDA says it has not authorized any robotic system specifically for cancer prevention or treatment, and that survival benefits versus traditional surgery have not been established.
How will the FDA regulate autonomous surgical robots?
That is not settled. The FDA’s November 2026 discussion paper asks for input on benefit and risk questions but is not guidance, and it does not name a pathway. Zimmer’s autonomous Monogram 510(k) is an early test.
Sources
- Medtronic, Hugo general surgery clearance, Nov 17, 2026 (primary): https://news.medtronic.com/2026-11-17-Medtronic-announces-FDA-clearance-of-general-surgery-procedures-for-the-Hugo-TM-robotic-assisted-surgery-RAS-system
- Medtronic, Hugo urology clearance, Dec 3, 2025 (primary): https://news.medtronic.com/2025-12-03-Medtronic-announces-FDA-clearance-of-Hugo-TM-robotic-assisted-surgery-system-for-urologic-surgical-procedures
- FDA De Novo order DEN250068 (Ottava), July 21, 2026 (primary): https://www.accessdata.fda.gov/cdrh_docs/pdf25/DEN250068.pdf
- J&J, Ottava US market authorization, July 22, 2026 (primary): https://www.jnj.com/media-center/press-releases/johnson-johnson-receives-fda-market-authorization-in-the-u-s-for-its-ottava-robotic-surgical-system
- FDA product classification NAY (primary): https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?id=NAY
- FDA 510(k) database K990144 (primary): https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K990144
- FDA 510(k) K260653, Dexter L6 (primary): https://www.accessdata.fda.gov/cdrh_docs/pdf26/K260653.pdf
- Intuitive, da Vinci 5 clearance, March 2024 (primary): https://investor.intuitivesurgical.com/news-releases/news-release-details/intuitive-announces-fda-clearance-fifth-generation-robotic
- CMR Surgical, Versius De Novo, October 2024 (primary): https://us.cmrsurgical.com/news/cmr-receives-fda-marketing-authorization-for-versius
- FDA, De Novo classification request page (primary): https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/de-novo-classification-request
- FDA, Premarket notification 510(k) page (primary): https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/premarket-notification-510k
- FDA, MDUFA V commitment letter (primary): https://www.fda.gov/media/158308/download
- FDA, Medical device user fee rates for FY2027, Federal Register July 30, 2026 (primary): https://www.federalregister.gov/documents/2026/07/30/2026-15335/medical-device-user-fee-rates-for-fiscal-year-2027
- FDA, Computer assisted surgical systems page (primary): https://www.fda.gov/medical-devices/surgery-devices/computer-assisted-surgical-systems
- FDA Brief, Feb 28, 2019 (primary): https://www.fda.gov/news-events/fda-brief/fda-brief-fda-cautions-patients-providers-about-using-robotically-assisted-surgical-devices
- FDA, autonomy and teleoperation discussion paper, November 2026 (primary): https://www.fda.gov/media/196129/download
- FDA, public workshop page, Dec 2 to 3, 2026 (primary): https://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/public-workshop-evaluating-benefit-risk-robotic-medical-devices-autonomous-or-remote-teleoperation
- FDA, draft guidance on robotically assisted surgical devices premarket submissions (primary, landing page): https://www.fda.gov/regulatory-information/search-fda-guidance-documents/robotically-assisted-surgical-devices-premarket-submissions
- American Hospital Association, Nov 9, 2026 (attributed, comment deadline and docket): https://www.aha.org/news/headline/2026-11-09-fda-seeks-comments-discussion-paper-about-benefits-and-risks-autonomous-robotic-medical-devices
- MedTech Dive, first Ottava install, Nov 20, 2026 (attributed): https://www.medtechdive.com/news/jj-to-install-first-ottava-robot-in-us-hospital/875343/
- MedTech Dive, Zimmer Monogram 510(k), Nov 20, 2026 (attributed): https://www.medtechdive.com/news/zimmer-submits-monogram-robot-to-fda/875347/
Related coverage
- Transferring a 510(k): What FDA’s Final Guidance Requires
- PMA Not Approvable Letter: What FDA Device Rejections Mean
- FDA Device Recall Classes: Class I, II and III Explained
- MiniMed Fit and Tandem Mobi Go Tubeless: The Patch Pump Race
- The Medical Device Companies to Know in 2026
- BioMed Nexus company directory
Get the daily briefing on what moved in biotech, pharma and medtech: subscribe to BioMed Nexus.


